Comparative Benchmarking
In the context of the broader market, RCKT competes directly with industry leaders such as FBRX and ZURA. With a market capitalization of $384.19M, it holds a significant position in the sector. When comparing efficiency, RCKT's gross margin of N/A stands against FBRX's N/A and ZURA's N/A. Such benchmarking helps identify whether Rocket Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
